Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital
- PMID: 34053144
- PMCID: PMC9290937
- DOI: 10.1111/jam.15166
Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital
Abstract
Aims: Klebsiella pneumoniae has been reported to develop increased antibiotic resistance. Ceftazidime-avibactam (CZA) is a novel antibiotic with activity against serine-lactamase. Here, we investigated the sensitivity of carbapenem-resistant K. pneumoniae (CRKP) to CZA and the mechanisms of drug resistance in our hospital.
Methods and results: Patient characteristics were obtained from medical records. K. pneumoniae and its antibiotic susceptibility were determined using the Vitek-2 Compact instrument. The antibiotic resistance genes KPC, NDM, OXA-48, VIM, IMP, CIM, SPM, TMB, SMB, SIM, AIM and DIM were detected using real-time PCR. Multilocus sequence typing was used for genetic RELATEDNESS analysis. In total, 121 CRKP strains were isolated from patients in the intensive care unit (51·2%), senior ward (12·4%) and neurosurgery department (10%). With an average age of 72·5 years, most patients were in care for respiratory (34·7%), brain (20·7%), digestive tract (13·2%) and cardiovascular (8·3%) diseases. Specimens were predominantly obtained from sputum (39·67%), urine (29·75%) and blood (6·61%).
Conclusion: Of 23 CZA-resistant CRKP strains (19·01%), ST11 being the most common at 56·52%, 11 NDM-1-positive (47·83%) and four NDM-5-positive (17·39%) strains were detected.
Significance and impact of the study: Our study indicates that CZA resistance occurs in ~19·01% CRKP strains and that blaNDM-1 and blaNDM-5 might be critical for resistance.
Keywords: Klebsiella pneumoniae; NDM-1; NDM-5; carbapenem resistance; ceftazidime-avibactam; epidemiology.
© 2021 The Authors. Journal of Applied Microbiology published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology.
Conflict of interest statement
No competing financial interest exists.
Figures



Similar articles
-
Carbapenem-resistant Klebsiella pneumoniae infections in Chinese children: in vitro activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study.Front Cell Infect Microbiol. 2025 Mar 26;15:1545999. doi: 10.3389/fcimb.2025.1545999. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40207055 Free PMC article.
-
Diverse modes of ceftazidime/avibactam resistance acquisition in carbapenem-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from a Chinese intensive care unit.Ann Clin Microbiol Antimicrob. 2025 May 30;24(1):35. doi: 10.1186/s12941-025-00800-z. Ann Clin Microbiol Antimicrob. 2025. PMID: 40448249 Free PMC article.
-
Molecular Mechanisms Driving the In Vivo Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.mSphere. 2021 Dec 22;6(6):e0085921. doi: 10.1128/mSphere.00859-21. Epub 2021 Dec 22. mSphere. 2021. PMID: 34935448 Free PMC article.
-
Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections.Expert Rev Anti Infect Ther. 2022 Nov;20(11):1389-1400. doi: 10.1080/14787210.2022.2128764. Epub 2022 Sep 28. Expert Rev Anti Infect Ther. 2022. PMID: 36150216 Review.
-
Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland.Eur J Clin Microbiol Infect Dis. 2024 Aug;43(8):1579-1587. doi: 10.1007/s10096-024-04859-y. Epub 2024 May 29. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38811482 Free PMC article. Review.
Cited by
-
First Report of Potentially Pathogenic Klebsiella pneumoniae from Serotype K2 in Mollusk Tegillarca granosa and Genetic Diversity of Klebsiella pneumoniae in 14 Species of Edible Aquatic Animals.Foods. 2022 Dec 15;11(24):4058. doi: 10.3390/foods11244058. Foods. 2022. PMID: 36553800 Free PMC article.
-
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5. Antimicrob Resist Infect Control. 2025. PMID: 39934901 Free PMC article.
-
Characterization of a mobilizable megaplasmid carrying multiple resistance genes from a clinical isolate of Pseudomonas aeruginosa.Front Microbiol. 2023 Nov 27;14:1293443. doi: 10.3389/fmicb.2023.1293443. eCollection 2023. Front Microbiol. 2023. PMID: 38088964 Free PMC article.
-
Prevalence and Characterization of Serratia marcescens Isolated from Clinical Bovine Mastitis Cases in Ningxia Hui Autonomous Region of China.Infect Drug Resist. 2023 May 4;16:2727-2735. doi: 10.2147/IDR.S408632. eCollection 2023. Infect Drug Resist. 2023. PMID: 37168514 Free PMC article.
-
Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-Resistant Enterobacteriaceae with Different Resistance Mechanisms.Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0026223. doi: 10.1128/aac.00262-23. Epub 2023 Jun 26. Antimicrob Agents Chemother. 2023. PMID: 37358468 Free PMC article.
References
-
- Barnes, M.D. , Winkler, M.L. , Taracila, M.A. , Page, M.G. , Desarbre, E. , Kreiswirth, B.N. , Shields, R.K. , Nguyen, M.H. et al. (2017) Klebsiella pneumoniae carbapenemase‐2 (KPC‐2), substitutions at ambler position Asp179, and resistance to ceftazidime‐avibactam: unique antibiotic‐resistant phenotypes emerge from β‐lactamase protein engineering. MBio 8, e00528‐17. - PMC - PubMed
-
- Carmeli, Y. , Armstrong, J. , Laud, P.J. , Newell, P. , Stone, G. , Wardman, A. and Gasink, L.B. (2016) Ceftazidime‐avibactam or best available therapy in patients with ceftazidime‐resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra‐abdominal infections (REPRISE): a randomized, pathogen‐directed, phase 3 study. The Lancet Infect Dis 16, 661–673. - PubMed
MeSH terms
Substances
Grants and funding
- 2020J05258/Fujian Natural Science Foundation
- 2020HSJJ09/High-level hospital foster grants from Fujian Provincial Hospital
- 2020GGA006/Health Science and Technology Program of Fujian Province
- (2017)510#/Fujian Province Intensive Care Medical Center Construction Project Grants from Fujian Provincial Hospital
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous